Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
413
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)

Anna KalffMyeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital/Monash University, Melbourne, Australia; ;Malignant Hematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Australia; View further author information
,
Tiffany KhongMyeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital/Monash University, Melbourne, Australia; View further author information
,
Sridurga MithraprabhuMyeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital/Monash University, Melbourne, Australia; View further author information
,
Krystal BerginMalignant Hematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Australia; View further author information
,
John ReynoldsAlfred Health and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia; View further author information
,
Kathryn M. BowenMalignant Hematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Australia; View further author information
,
Anjan ThakurtaCelgene Corporation, Summit, NJ, USA; View further author information
,
Roberto GuzmanCelgene Corporation, San Diego, CA, USAView further author information
,
Maria WangCelgene Corporation, San Diego, CA, USAView further author information
,
Suzana CoutoCelgene Corporation, San Diego, CA, USAView further author information
,
Yan RenCelgene Corporation, San Diego, CA, USAView further author information
&
Andrew SpencerMyeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital/Monash University, Melbourne, Australia; ;Malignant Hematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Australia; Correspondence[email protected]
View further author information
 show all
Pages 2143-2151 | Received 07 Nov 2018, Accepted 26 Dec 2018, Published online: 11 Jun 2019

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jonathan Feld, Douglas Tremblay, Shyamala C. Navada & Lewis R. Silverman. (2023) Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. Leukemia & Lymphoma 64:3, pages 525-539.
Read now
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, Patricia Walker, Anthony Schwarer, Andrew W. Roberts, Philip Campbell, Robin Filshie, Sam Norton, John Reynolds, Mary Young, William Pierceall, Anjan Thakurta, Manman Guo, Udo Oppermann, Maria Wang, Yan Ren, Nola Kennedy, Samir Parekh & Andrew Spencer. (2021) Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leukemia & Lymphoma 62:12, pages 2981-2991.
Read now

Articles from other publishers (10)

Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, Laura Szalewska, Bartłomiej Baumert & Bogusław Machaliński. (2023) Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. Cancers 15:3, pages 963.
Crossref
Larissa Haertle, Santiago Barrio, Umair Munawar, Seungbin Han, Xiang Zhou, Michal Simicek, Cornelia Vogt, Marietta Truger, Rafael Alonso Fernandez, Maximilian Steinhardt, Julia Weingart, Renata Snaurova, Silvia Nerreter, Eva Teufel, Andoni Garitano-Trojaola, Matteo Da Viá, Yanira Ruiz-Heredia, Andreas Rosenwald, Niccolò Bolli, Roman Hajek, Peter Raab, Marc S. Raab, Niels Weinhold, Claudia Haferlach, Thomas Haaf, Joaquin Martinez-Lopez, Hermann Einsele, Leo Rasche & K. Martin Kortüm. (2023) Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma. Clinical Cancer Research 29:1, pages 279-288.
Crossref
Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken & Elke De Bruyne. (2022) Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?. Frontiers in Oncology 12.
Crossref
Guillermo Garcia-Manero, Hartmut Döhner, Andrew H. Wei, Ignazia La Torre, Barry Skikne, CL Beach & Valeria Santini. (2022) Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma Myeloma and Leukemia 22:4, pages 236-250.
Crossref
Larissa Haertle, Santiago BarrioUmair Munawar, Seungbin Han, Xiang ZhouCornelia VogtRafael Alonso FernándezMax Bittrich, Yanira Ruiz-HerediaMatteo Da Viá, Josip ZovkoAndoni Garitano-TrojaolaNiccolò BolliAnna RuckdeschelThorsten StühmerManik ChatterjeeMiriam KullJan Krönke, Xabier AgirreJose I. Martin-Subero, Peter Raab, Hermann EinseleLeo Rasche, Joaquin Martinez-LopezThomas Haaf & K. Martin Kortüm. (2021) Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood 138:18, pages 1721-1726.
Crossref
Suvir Singh, Kunal Jain, Rintu Sharma, Jagdeep Singh & Davinder Paul. (2021) Epigenetic Modifications in Myeloma: Focused Review of Current Data and Potential Therapeutic Applications. Indian Journal of Medical and Paediatric Oncology 42:05, pages 395-405.
Crossref
Marcos de Lima, Gail J. Roboz, Uwe Platzbecker, Charles Craddock & Gert Ossenkoppele. (2021) AML and the art of remission maintenance. Blood Reviews 49, pages 100829.
Crossref
Anaïs Schavgoulidze, Titouan Cazaubiel, Aurore Perrot, Hervé Avet-Loiseau & Jill Corre. (2021) Multiple Myeloma: Heterogeneous in Every Way. Cancers 13:6, pages 1285.
Crossref
Jack Khouri, Beth M Faiman, Dale Grabowski, Reda Z Mahfouz, Shahper N Khan, Wei Wei, Jason Valent, Robert Dean, Christy Samaras, Babal K Jha, Hillard Lazarus, Erica L. Campagnaro, Ehsan Malek, Janice Reed, Mary Ann Karam, Kimberly Hamilton, Sherry Fada, Matt Kalaycio, Hien Liu, Ronald Sobecks, Yogen Saunthararajah, Yap Chew, Mohammed Orloff & Frederic J Reu. (2021) DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Seminars in Hematology 58:1, pages 45-55.
Crossref
Sridurga Mithraprabhu, Rachel Morley, Tiffany Khong, Anna Kalff, Krystal Bergin, Jay Hocking, Ioanna Savvidou, Kathryn M. Bowen, Malarmathy Ramachandran, Kawa Choi, Boris Ka Leong Wong, John Reynolds & Andrew Spencer. (2019) Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia 33:8, pages 2022-2033.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.